Hiroaki Ishida

Dr. Hiroaki Ishida

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CYChisato Yoshikawa
Chisato Yoshikawa
HIHiroaki Ishida
Hiroaki Ishida
NONami Ohashi
Nami Ohashi
TIToshimasa Itoh
Toshimasa Itoh
Peroxisome proliferator-activated receptor γ (PPARγ) is a molecular target of metabolic syndrome and inflammatory disease. PPARγ is an important nuclear receptor and numerous PPARγ ligands were developed to date; thus, efficient assay methods are important. Here, we investigated the incorporation of 7-diethylamino coumarin into the PPARγ agonist rosiglitazone and used the compound in a binding assay for PPARγ. PPARγ-ligand-incorporated 7-methoxycoumarin, 1, showed weak fluorescence intensity in a previous report. We synthesized PPARγ-ligand-incorporating coumarin, 2, in this report, and it enhanced the fluorescence intensity. The PPARγ ligand 2 maintained the rosiglitazone activity. The obtained partial agonist 6 appeared to act through a novel mechanism. The fluorescence intensity of 2 and 6 increased by binding to the ligand binding domain (LBD) of PPARγ and the affinity of reported PPARγ ligands were evaluated using the probe.

21 February 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
TYTetsuya Yano
Tetsuya Yano
TYTakahiro Yamada
Takahiro Yamada
HIHiroaki Ishida
Hiroaki Ishida
NONami Ohashi
Nami Ohashi
TIToshimasa Itoh
Toshimasa Itoh
Inspired by the chemical reactivity of apalutamide, an efficient method for N-terminal cysteine bioconjugation with 2-cyanopyridine derivatives has been developed.

12 December 2022 in ACS Omega
Verified
Journal Article
Open access
MTMami Takyo
Mami Takyo
YSYumi Sato
Yumi Sato
NHNaoya Hirata
Naoya Hirata
KTKeisuke Tsuchiya
Keisuke Tsuchiya
HIHiroaki Ishida
Hiroaki Ishida
YDYosuke Demizu
Yosuke Demizu
The vitamin D receptor (VDR) is a nuclear receptor, which is involved in several physiological processes, including differentiation and bone homeostasis. The VDR is a promising target for the development of drugs against cancer and bone-related diseases. To date, several VDR antagonists, which bind to the ligand binding domain of the VDR and compete with the endogenous agonist 1 alpha,25(OH)D3, have been reported. However, these ligands contain a secosteroidal skeleton, which is chemically unstable and complicated to synthesize. A few VDR antagonists with a nonsecosteroidal skeleton have been reported. Alternative inhibitors against VDR transactivation that act via different mechanisms are desirable. Here, we developed peptide-based VDR inhibitors capable of disrupting the VDR-coactivator interaction. It was reported that helical SRC2-3 peptides strongly bound to the VDR and competed with the coactivator in vitro. Therefore, we designed and synthesized a series of SRC2-3 derivatives by the introduction of nonproteinogenic amino acids, such as beta-amino acids, and by side-chain stapling to stabilize helical structures and provide resistance against digestive enzymes. In addition, conjugation with a cell-penetrating peptide increased the cell membrane permeability and was a promising strategy for intracellular VDR inhibition. The nona-arginine-conjugated peptides 24 with side-chain stapling and 25 with cyclic beta-amino acids showed strong intracellular VDR inhibitory activity, resulting in suppression of the target gene expression and inhibition of the cell differentiation of HL-60 cells. Herein, the peptide design, structure-activity relationship (SAR) study, and biological evaluation of the peptides are described.

30 March 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HKHiroyuki Kojima
Hiroyuki Kojima
RYRyota Yanagi
Ryota Yanagi
EHEri Higuchi
Eri Higuchi
MYMami Yoshizawa
Mami Yoshizawa
TSTomoyuki Shimodaira
Tomoyuki Shimodaira
TIToshimasa Itoh
Toshimasa Itoh

25 March 2023 in Asian Journal of Organic Chemistry
Verified
Journal Article
Closed access
MSMiyu Sekine
Miyu Sekine
HIHiroaki Ishida
Hiroaki Ishida
TIToshimasa Itoh
Toshimasa Itoh

2 April 2025 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Open access
PDF file
DEDaichi Egawa
Daichi Egawa
HIHiroaki Ishida
Hiroaki Ishida
KKKazuaki Katakawa
Kazuaki Katakawa
Piperine has been investigated for a diverse array of biological effects, including a potential role in modulating peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that plays a pivotal role in regulating lipid and glucose metabolism. This study conducted a comprehensive co-crystallographic analysis of the complex of piperine with the PPARγ ligand-binding domain (PPARγ-LBD), with the objective of elucidating the precise binding interactions of piperine. The co-crystal structure revealed that piperine binds within the ligand-binding pocket of PPARγ-LBD via hydrogen-bonding and hydrophobic interactions with residues of the ligand-binding site. Notably, in contrast to conventional full agonists, piperine does not directly stabilize helix H12. This could contribute to the comparatively weaker agonistic activity of piperine. The results of this study also suggest that piperine binding facilitates a role as a partial agonist or even an antagonist under certain physiological conditions. Collectively, these findings contribute to a greater understanding of the manner in which piperine modulates PPARγ function and its potential as a therapeutic candidate for the treatment of metabolic disorders. Given its natural origin and relatively minimal side-effect profile, piperine and its derivatives could be promising alternatives to synthetic PPARγ modulators such as thiazolidinediones, which have significant side effects.